Wang, Victoria E <br/><br/>
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  12 2019 
 - 7202-7217 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-18-2779  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis<br/>Autocrine Communication<br/>Biomarkers, Tumor--metabolism<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Proliferation<br/>Drug Resistance, Neoplasm<br/>Fibroblast Growth Factor 1--metabolism<br/>Gene Expression Regulation, Neoplastic<br/>High-Throughput Screening Assays<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>MAP Kinase Kinase 1--antagonists & inhibitors<br/>Melanoma--drug therapy<br/>Mice<br/>Mice, Nude<br/>Prognosis<br/>Proto-Oncogene Proteins B-raf--antagonists & inhibitors<br/>Receptor, Fibroblast Growth Factor, Type 1--metabolism<br/>Survival Rate<br/>Tumor Cells, Cultured<br/>Xenograft Model Antitumor Assays